In vivo retargeting of adenovirus type 5 to ?v?6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery
A key impediment to successful cancer therapy with adenoviral vectors is the inefficient transduction of malignant tissue in vivo. Compounding this problem is the lack of cancer-specific targets, coupled with a shortage of corresponding high-efficiency ligands, permitting selective retargeting. The...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
2009-07.
|
| Subjects: | |
| Online Access: | Get fulltext |